Global Allied Pharmaceuticals
Global Allied Pharmaceuticals (GAP) is dedicated to advancing pharmaceutical development and clinical research. They offer a comprehensive range of services including clinical trial development, safety monitoring, data management, and regulatory compliance, with a focus on efficiency, quality, and global standards. Their mission is to support clients in achieving successful regulatory approvals and market entry through expert guidance and innovative solutions.
Industries
Nr. of Employees
Very Large (1000+)
Global Allied Pharmaceuticals
Products
Solubility enhancement technology for chemotherapeutic agents
A formulation/modality intended to increase solubility of chemotherapeutic and other poorly soluble compounds (class III–IV) to improve delivery characteristics.
Immune Oncology Platform
Comprehensive platform offering advanced solutions including Antibody Drug Conjugates, vaccines, and advanced CMC solutions for oncology development.
TEXTBOOK OF IMMUNE-ONCOLOGY IN TREATMENT OF SOLID TUMORS
Textbook covering immune-oncology in the treatment of solid tumors.
Qualified Person
GAP provides Qualified Person for Pharmacovigilance (QPPV) services for clients entering the European Union (EU) market to ensure strong administration of Marketing Authorization Holder's pharmacovigilance frameworks.
Qualified Person for Pharmacovigilance (QPPV) Services
GAP provides Qualified Person for Pharmacovigilance (QPPV) services for clients entering the European Union market to ensure administration of Marketing Authorization Holder's pharmacovigilance frameworks.
Antibody-Drug Conjugate (ADC) Technology
Proprietary, industry-leading antibody-drug conjugate technology employing monoclonal antibodies specific for tumor-associated antigens, stable linkers, and synthetic cytotoxic agents to treat cancer.
Solubility enhancement technology for chemotherapeutic agents
A formulation/modality intended to increase solubility of chemotherapeutic and other poorly soluble compounds (class III–IV) to improve delivery characteristics.
Immune Oncology Platform
Comprehensive platform offering advanced solutions including Antibody Drug Conjugates, vaccines, and advanced CMC solutions for oncology development.
TEXTBOOK OF IMMUNE-ONCOLOGY IN TREATMENT OF SOLID TUMORS
Textbook covering immune-oncology in the treatment of solid tumors.
Qualified Person
GAP provides Qualified Person for Pharmacovigilance (QPPV) services for clients entering the European Union (EU) market to ensure strong administration of Marketing Authorization Holder's pharmacovigilance frameworks.
Qualified Person for Pharmacovigilance (QPPV) Services
GAP provides Qualified Person for Pharmacovigilance (QPPV) services for clients entering the European Union market to ensure administration of Marketing Authorization Holder's pharmacovigilance frameworks.
Antibody-Drug Conjugate (ADC) Technology
Proprietary, industry-leading antibody-drug conjugate technology employing monoclonal antibodies specific for tumor-associated antigens, stable linkers, and synthetic cytotoxic agents to treat cancer.
Services
Operational and management support for clinical studies including startup, monitoring, supplies, study conduct, and close-out activities for phases I–IV.
End-to-end CDM services to generate source-verified, accessible clinical data with processes to reduce total cost of ownership and improve process efficiency.
Individual and aggregate case processing, signal detection, surveillance activities, safety reporting, and lifecycle safety monitoring.
Medical oversight services including SAE management, participation in DMCs/steering committees, study-level data review, and contribution to CSRs and database lock activities.
Investigator and CRC relationship management, site training and certification, GCP training, and on-site support to ensure compliance and efficient study execution.
Recruitment planning, identification of potential subjects from databases, management of complex inclusion/exclusion criteria, and retention strategies.
Operational and management support for clinical studies including startup, monitoring, supplies, study conduct, and close-out activities for phases I–IV.
End-to-end CDM services to generate source-verified, accessible clinical data with processes to reduce total cost of ownership and improve process efficiency.
Individual and aggregate case processing, signal detection, surveillance activities, safety reporting, and lifecycle safety monitoring.
Medical oversight services including SAE management, participation in DMCs/steering committees, study-level data review, and contribution to CSRs and database lock activities.
Investigator and CRC relationship management, site training and certification, GCP training, and on-site support to ensure compliance and efficient study execution.
Recruitment planning, identification of potential subjects from databases, management of complex inclusion/exclusion criteria, and retention strategies.
Expertise Areas
- Clinical trial management
- Clinical data management
- Biostatistics
- Pharmacovigilance and drug safety
Key Technologies
- Clinical data management platforms
- Pharmacovigilance and safety databases (ICSR and aggregate reporting)
- Signal detection and safety surveillance methods
- Biostatistical analysis and study-level statistical review